Aziyo biologics announces closing of $14.0 million private placement

Silver spring, md., dec. 08, 2021 (globe newswire) -- aziyo biologics, inc. (the “company”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the closing of the previously announced private investment in public equity (pipe) financing. the company received aggregate gross proceeds of approximately $14.0 million, before deducting offering expenses. the pipe financing was led by a fund affiliated with birchview capital, with participation from existing investors including funds affiliated with deerfield management company and highcape capital.
AZYO Ratings Summary
AZYO Quant Ranking